Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark S Sands

Showing results (11-20 of 105) with videos related to

Pageof 11
Sort By:
Expert Opinion on Drug Safety|August 9, 2003
Safety of adeno-associated virus gene therapy vectors: a current evaluationPaul E Monahan, Karin Jooss, Mark S Sands
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2002
VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipientsPampee P Young, A Alex Hofling, Mark S Sands
Neuroscience Letters|March 26, 2021
Krabbe disease: New hope for an old diseaseAllison M Bradbury, Ernesto R Bongarzone, Mark S Sands
Experimental Neurology|June 12, 2004
VEGF disrupts the neonatal blood-brain barrier and increases life span after non-ablative BMT in a murine model of congenital neurodegeneration caused by a lysosomal enzyme deficiencyPampee P Young, Corinne R Fantz, Mark S Sands
Human Gene Therapy|March 16, 2017
Recombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal ModelsRandy J Chandler, Mark S Sands, Charles P Venditti
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 15, 2004
Human CD34+ hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage diseaseA Alex Hofling, Steven Devine, Carole Vogler, et al.
Human Molecular Genetics|March 23, 2011
Combination therapies for lysosomal storage disease: is the whole greater than the sum of its parts?Jacqueline A Hawkins-Salsbury, Adarsh S Reddy, Mark S Sands
Biochimica Et Biophysica Acta|June 11, 2013
Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease)Jacqueline A Hawkins-Salsbury, Jonathan D Cooper, Mark S Sands
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 8, 2003
Biodistribution and efficacy of donor T lymphocytes in a murine model of lysosomal storage diseasePampee P Young, Carole Vogler, A Alex Hofling, et al.
Blood|October 31, 2002
Engraftment of human CD34+ cells leads to widespread distribution of donor-derived cells and correction of tissue pathology in a novel murine xenotransplantation model of lysosomal storage diseaseA Alex Hofling, Carole Vogler, Michael H Creer, et al.
Pageof 11

Showing results (11-20 of 105) with videos related to

Sort By:
Pageof 11
Expert Opinion on Drug Safety|August 9, 2003
Safety of adeno-associated virus gene therapy vectors: a current evaluationPaul E Monahan, Karin Jooss, Mark S Sands
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2002
VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipientsPampee P Young, A Alex Hofling, Mark S Sands
Neuroscience Letters|March 26, 2021
Krabbe disease: New hope for an old diseaseAllison M Bradbury, Ernesto R Bongarzone, Mark S Sands
Experimental Neurology|June 12, 2004
VEGF disrupts the neonatal blood-brain barrier and increases life span after non-ablative BMT in a murine model of congenital neurodegeneration caused by a lysosomal enzyme deficiencyPampee P Young, Corinne R Fantz, Mark S Sands
Human Gene Therapy|March 16, 2017
Recombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal ModelsRandy J Chandler, Mark S Sands, Charles P Venditti
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 15, 2004
Human CD34+ hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage diseaseA Alex Hofling, Steven Devine, Carole Vogler, et al.
Human Molecular Genetics|March 23, 2011
Combination therapies for lysosomal storage disease: is the whole greater than the sum of its parts?Jacqueline A Hawkins-Salsbury, Adarsh S Reddy, Mark S Sands
Biochimica Et Biophysica Acta|June 11, 2013
Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease)Jacqueline A Hawkins-Salsbury, Jonathan D Cooper, Mark S Sands
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 8, 2003
Biodistribution and efficacy of donor T lymphocytes in a murine model of lysosomal storage diseasePampee P Young, Carole Vogler, A Alex Hofling, et al.
Blood|October 31, 2002
Engraftment of human CD34+ cells leads to widespread distribution of donor-derived cells and correction of tissue pathology in a novel murine xenotransplantation model of lysosomal storage diseaseA Alex Hofling, Carole Vogler, Michael H Creer, et al.
Pageof 11